Alexion Joins Eurordis, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2013

  Alexion Joins Eurordis, NORD and Patient Organizations Worldwide in
  Celebrating Rare Disease Day 2013

  -- Global Effort to Raise Awareness and Improve Diagnosis and Treatment of
                              Rare Disorders --

Business Wire

CHESHIRE, Conn. -- February 28, 2013

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), joins the European Organization
for Rare Diseases (EURORDIS), the National Organization for Rare Disorders
(NORD) and patient organizations worldwide in celebrating Rare Disease Day
2013, a global effort to focus attention on rare diseases, their profound
impact on patients, and the need for improved diagnosis and treatment. The
theme of this year’s celebration, “Rare Disorders without Borders,” aligns
with Alexion’s mission of developing and delivering life-transforming
therapies for patients worldwide who suffer from severe, life-threatening
diseases that are ultra-rare.

“On Rare Disease Day, we are breaking isolation and raising awareness.
Patients worldwide are not alone. We urge all stakeholders to reach across
borders and find common solutions to living with serious, chronic and
life-threatening rare diseases,” said Yann Le Cam, Chief Executive Officer,
EURORDIS. “Working together we can promote rare diseases as a public health
priority, so to improve patients’ access to diagnosis and treatment.”

Many rare and ultra-rare diseases are chronic, progressive and marked by
continuing pain, severe disability and high mortality rates. Diagnosing and
managing these rare diseases is often made difficult by a lack of scientific
knowledge, research and medical innovation. Few physicians are familiar with
diagnosing and treating these illnesses, which frequently leads to missed,
delayed or inaccurate diagnoses even when an approved, effective therapy is
available.^1 Because of this, it is important to educate the medical community
through disease awareness programs and diagnostic initiatives to identify
patients suffering from rare and ultra-rare diseases as early as possible.

"Like many patients coping with a rare or ultra-rare disease, it took several
months for our daughter to get an accurate diagnosis,” said Denise Schmidt,
mother of a young adult diagnosed with atypical hemolytic uremic syndrome
(aHUS), a chronic, ultra-rare and life-threatening disease that can
progressively damage vital organs. “Increasing awareness among physicians and
patients is a vital first step to ensuring our loved ones receive the best
treatment and care.”

Alexion developed Soliris^® (eculizumab), a first-in-class terminal complement
inhibitor, from the laboratory through regulatory approval and
commercialization. Soliris is approved in the US, European Union, Japan and
other countries as the first and only treatment for patients with paroxysmal
nocturnal hemoglobinuria (PNH), a debilitating, life-threatening and
ultra-rare blood disorder. Soliris is also approved in the US and the European
Union as the first and only treatment for patients with atypical hemolytic
uremic syndrome (aHUS), a debilitating and life-threatening ultra-rare genetic

“We understand that every day is Rare Disease Day for patients and families
who suffer from severe and life-threatening ultra-rare disorders and often
live without hope because an effective treatment option is not available,”
said Leonard Bell, M.D., Chief Executive Officer of Alexion. "The employees of
Alexion are committed to developing and delivering therapies that can
transform the lives of these patients. We now serve patients in 50 countries
by focusing on disease education to help patients with PNH and aHUS receive an
accurate diagnosis and appropriate treatment. At the same time, we continue to
invest in research and development with the goal of providing highly
innovative therapies to patients with additional severe and life-threatening
disorders, which also happen to be extremely rare.”

Bringing Hope Across the Globe

Alexion is currently developing five highly innovative therapeutics, including
eculizumab (Soliris^®), which are being investigated in nine severe and
life-threatening ultra-rare disorders. The company’s development programs are
solely focused on:

  *Severe disorders with devastating and life-threatening medical
  *Disorders with ineffective, or no treatment options
  *Disorders that are ultra-rare and affect very small numbers of patients

To learn more about Rare Disease Day, visitwww.rarediseaseday.usfor U.S.
activities and www.rarediseaseday.orgfor global activities.

About Rare and Ultra-Rare Disorders

In the United States, a disease is defined as rare if it affects fewer than
650 patients per million of population.^2 The European Union definition of a
rare disease is one that affects fewer than five patients per 10,000 of
population.^3 In contrast, a disease is generally considered to be ultra-rare
if it affects fewer than 20 patients per million of population^4 (one patient
per 50,000) – and most ultra-rare diseases affect far fewer people than this.

Despite the very small numbers of patients they affect, the impact of these
rare and ultra-rare diseases on patients, their families, and society is
profound, as many are severe, chronic and progressive, with high mortality
rates. Patients with severe and life-threatening ultra-rare diseases often
live without hope, have no effective treatment options and may face premature

About aHUS

aHUS is a chronic, ultra-rare, and life-threatening disease in which a genetic
deficiency in one or more complement regulatory genes causes chronic
uncontrolled complement activation, resulting in complement-mediated
thrombotic microangiopathy (TMA), the formation of blood clots in small blood
vessels throughout the body.^5,6 Permanent, uncontrolled complement activation
in aHUS causes a life-long risk for TMA, which leads to sudden, catastrophic,
and life-threatening damage to the kidney, brain, heart, and other vital
organs, and premature death.^5,7Sixty-five percent of all patients with aHUS
require kidney dialysis, have permanent kidney damage or die within the first
year after diagnosis despite plasma exchange or plasma infusion (PE/PI).^8,9
The majority of patients with aHUS who receive a kidney transplant commonly
experience subsequent systemic TMA, resulting in a 90% transplant failure rate
in these TMA patients.^10

aHUS affects both children and adults.^11Complement-mediated TMA also causes
reduction in platelet count (thrombocytopenia) and red blood cell destruction
(hemolysis). While mutations have been identified in at least ten different
complement regulatory genes, mutations are not identified in 30-50% of
patients with a confirmed diagnosis of aHUS.^11

About PNH

PNH is an ultra-rare blood disorder in which chronic, uncontrolled activation
of complement, a component of the normal immune system, results in hemolysis
(destruction of the patient's red blood cells). PNH strikes people of all
ages, with an average age of onset in the early 30s.^12 Approximately 10% of
all patients first develop symptoms at 21 years of age or younger.^13 PNH
develops without warning and can occur in men and women of all races,
backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis
ranging from one to more than 10 years.^14 In the period of time before
Soliris was available, it had been estimated that approximately one-third of
patients with PNH did not survive more than five years from the time of
diagnosis.^12 PNH has been identified more commonly among patients with
disorders of the bone marrow, including aplastic anemia (AA) and
myelodysplastic syndromes (MDS).^15-17 In patients with thrombosis of unknown
origin, PNH may be an underlying cause.^12

About Soliris

Soliris is a first-in-class terminal complement inhibitor developed from the
laboratory through regulatory approval and commercialization by Alexion.
Soliris is approved in the U.S., European Union, Japan and other countries as
the first and only treatment for patients with paroxysmal nocturnal
hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood
disorder, characterized by complement-mediated hemolysis (destruction of red
blood cells). Soliris is indicated to reduce hemolysis.

Soliris is also approved in the U.S. and the European Union as the first and
only treatment for patients with atypical hemolytic uremic syndrome (aHUS), a
debilitating, ultra-rare and life-threatening genetic disorder characterized
by complement-mediated thrombotic microangiopathy, or TMA (blood clots in
small vessels). Soliris is indicated to inhibit complement-mediated TMA. The
effectiveness of Soliris in aHUS is based on the effects on TMA and renal
function. Prospective clinical trials in additional patients are ongoing to
confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated
for the treatment of patients with Shiga toxinE. colirelated hemolytic
uremic syndrome (STEC-HUS).

Alexion's breakthrough approach in complement inhibition has received the
pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for
Best Biotechnology Product with broad implications for future biomedical
research, and the 2009 Prix Galien France Award in the category of Drugs for
Rare Diseases. More information, including the full prescribing information on
Soliris, is available

Important Safety Information

The US product label for Soliris includes a boxed warning: "Life-threatening
and fatal meningococcal infections have occurred in patients treated with
Soliris. Meningococcal infection may become rapidly life-threatening or fatal
if not recognized and treated early. Comply with the most current Advisory
Committee on Immunization Practices (ACIP) recommendations for meningococcal
vaccination in patients with complement deficiencies. Immunize patients with a
meningococcal vaccine at least 2 weeks prior to administering the first dose
of Soliris, unless the risks of delaying Soliris therapy outweigh the risk of
developing a meningococcal infection. (See Serious Meningococcal Infections
(5.1) for additional guidance on the management of meningococcal infection.)
Monitor patients for early signs of meningococcal infections and evaluate
immediately if infection is suspected. Soliris is available only through a
restricted program under a Risk Evaluation and Mitigation Strategy (REMS).
Under the Soliris REMS, prescribers must enroll in the program (5.2).
Enrollment in the Soliris REMS program and additional information are
available by telephone: 1-888-soliris (1-888-765-4747)."

In patients with PNH, the most frequently reported adverse events observed
with Soliris treatment in clinical studies were headache, nasopharyngitis
(runny nose), back pain and nausea. Soliris treatment of patients with PNH
should not alter anticoagulant management because the effect of withdrawal of
anticoagulant therapy during Soliris treatment has not been established. In
patients with aHUS, the most frequently reported adverse events observed with
Soliris treatment in clinical studies were hypertension, upper respiratory
tract infection, diarrhea, headache, anemia, vomiting, nausea, urinary tract
infection, and leukopenia. Please see full prescribing information for
Soliris, including boxed WARNING regarding risk of serious meningococcal

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on
serving patients with severe and ultra-rare disorders through the innovation,
development and commercialization of life-transforming therapeutic products.
Alexion is the global leader in complement inhibition and has developed and
markets Soliris^®(eculizumab) as a treatment for patients with PNH and aHUS,
two debilitating, ultra-rare and life-threatening disorders caused by chronic
uncontrolled complement activation. Soliris is currently approved in more than
40 countries for the treatment of PNH, and in the United States and the
European Union for the treatment of aHUS. Alexion is evaluating other
potential indications for Soliris and is developing four other highly
innovative biotechnology product candidates, which are being investigated
across nine severe and ultra-rare disorders beyond PNH and aHUS. This press
release and further information about Alexion Pharmaceuticals, Inc. can be



1. European survey on diagnosis and access to care:

2. US Food and Drug Administration’s Definition of Disease Prevalence for
Therapies Qualifying Under Orphan Drug Act:

OF THE COUNCIL of 16 December 1999 on orphan medicinal products and from
2011 on the application of patients’ rights in cross-border healthcare

4. Definition from the UK National Institute for Clinical Effectiveness
(NICE). 2004. Citizen Council Report on Ultra-Orphan Drugs. Available at and as defined in the following documents: Wales
Medicines Strategy Group (AWMSG); Recommendations for a Belgian Plan for Rare
Diseases; the EMINET Report commissioned by the European Commission’s
Directorate General Enterprise and Industry, the European Union Committee of
Experts on Rare Diseases’ (EUCERD)

5. Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin
Nephrol Hypertens. 2010;19(3):242-7.

6. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and
initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr
Nephrol. 2009;24:687-96.

7. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int.

8. Caprioli J, Noris M, Brioschi S, et al. The impact of MCP, CFH, and IF
mutations on clinical presentation, response to treatment, and outcome. Blood.

9. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical
hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:673-81.

10. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in
patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic
significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88-99.

11. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement
abnormalities in sporadic and familial aHUS and their impact on clinical
phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859.

12. Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal
haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996:

13. Parker C, Omine M, Richards S, et al. Diagnosis and management of
paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699-3709.

14. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of
paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.

15. Wang H, Chuhjo T, Yasue S, Omine M, Naka S. Clinical significance of a
minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone
marrow failure syndrome. Blood. 2002;100 (12):3897-3902.

16. Iwanga M, Furukawa K, Amenomori T, et al. Paroxysmal nocturnal
haemoglobinuria clones in patients with myelodysplastic syndromes. Br J
Haematol. 1998;102(2):465-474.

17. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between
bone marrow failure syndromes and the presence of glycophosphatidyl
inositol-anchored protein-deficient clones. Br J Haematol. 2001;115:1015-1022.

Photos/Multimedia Gallery Available:



Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Executive Director, Corporate Communications
Kim Diamond, 203-439-9600
Director, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.